GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5616344A
(en)
*
|
1994-06-14 |
1997-04-01 |
Fuisz Technologies Ltd. |
Apparatus and process for strengthening low density compression dosage units and product therefrom
|
CZ293062B6
(cs)
*
|
1997-09-25 |
2004-01-14 |
Bayer Aktiengesellschaft |
Léčivo s regulovaným uvolněním aktivní sloučeniny
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
AU2349999A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
WO1999038504A1
(en)
*
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
WO1999038499A2
(en)
*
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
|
AU2483499A
(en)
*
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (+)-bupropion
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6096341A
(en)
*
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6033686A
(en)
*
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
USD430285S
(en)
*
|
1999-04-16 |
2000-08-29 |
Merck & Co., Inc. |
Tablet
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
EP1790334A3
(de)
*
|
1999-11-02 |
2008-02-20 |
Depomed, Inc. |
Pharmakologische Induzierung vom Verdauungsmodus zur verbesserten Arzneistoffverabreichung an den Magen
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
WO2002062299A2
(en)
*
|
2001-02-08 |
2002-08-15 |
Andrx Pharmaceuticals, Inc. |
Improved controlled release oral dosage form
|
ITMI20011457A1
(it)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
US7109198B2
(en)
*
|
2002-05-17 |
2006-09-19 |
Duke University |
Method for treating obesity
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
US20040096497A1
(en)
*
|
2002-11-19 |
2004-05-20 |
Ponder Garratt W. |
Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
PL1617832T3
(pl)
*
|
2003-04-29 |
2009-01-30 |
Orexigen Therapeutics Inc |
Kompozycje wpływające na utratę wagi
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
ME00391B
(me)
*
|
2003-08-08 |
2011-10-10 |
Biovail Laboratories Int Srl |
Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
|
US7429580B2
(en)
|
2004-01-13 |
2008-09-30 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US8586085B2
(en)
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
GB0425445D0
(en)
*
|
2004-11-18 |
2004-12-22 |
Smithkline Beecham Corp |
Novel compositions
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
ZA200711123B
(en)
*
|
2005-06-27 |
2009-08-26 |
Biovail Lab Int Srl |
Modified-release formulations of a bupropion salt
|
CN101374507A
(zh)
*
|
2005-10-14 |
2009-02-25 |
H.隆德贝克有限公司 |
含有依他普仑和安非他酮的稳定药物制剂
|
EA200801081A1
(ru)
*
|
2005-10-14 |
2008-10-30 |
Х. Лундбекк А/С |
Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
|
EP3132792B1
(de)
|
2005-11-22 |
2019-09-11 |
Nalpropion Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur erhöhung der insulinempfindlichkeit
|
PL1954241T3
(pl)
*
|
2005-11-28 |
2013-03-29 |
Orexigen Therapeutics Inc |
Formulacja zonisamidu o przedłużonym uwalnianiu
|
CA2638735A1
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods to identify inhibitors of the unfolded protein response
|
EP1996118A4
(de)
|
2006-03-07 |
2013-03-06 |
Osteoscreen Ip Llc |
Stärkung von knochen und knorpel durch hmg-co-a-reduktase-inhibitor
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
CA2655139A1
(en)
|
2006-06-13 |
2008-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Epoxide inhibitors of cysteine proteases
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US20100008987A1
(en)
*
|
2006-08-21 |
2010-01-14 |
Pasula Basavaiah Chowdary |
Modified Release Pharmaceutical Composition of Bupropion Hydrochloride
|
AU2007319472B2
(en)
|
2006-11-09 |
2013-01-17 |
Nalpropion Pharmaceuticals Llc |
Methods Of Administering Weight Loss Medications
|
KR101479324B1
(ko)
|
2006-11-09 |
2015-01-05 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
NZ580250A
(en)
|
2007-04-09 |
2012-05-25 |
Sunovion Pharmaceuticals Inc |
Methods and compositions comprising desmethylvenlafaxine or duloxetine for treating sleep-related breathing disorders
|
WO2008156749A1
(en)
*
|
2007-06-18 |
2008-12-24 |
The General Hospital Corporation |
Combination therapy for depression
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
KR101616246B1
(ko)
|
2008-01-25 |
2016-05-02 |
그뤼넨탈 게엠베하 |
약제학적 투여형
|
WO2009111031A2
(en)
|
2008-03-04 |
2009-09-11 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
PL2273983T3
(pl)
|
2008-05-09 |
2017-01-31 |
Grünenthal GmbH |
Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
|
US20110144145A1
(en)
|
2008-05-30 |
2011-06-16 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
JP5667183B2
(ja)
|
2009-07-22 |
2015-02-12 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
加熱溶融押出成型した制御放出性投与剤型
|
WO2011009604A1
(en)
|
2009-07-22 |
2011-01-27 |
Grünenthal GmbH |
Oxidation-stabilized tamper-resistant dosage form
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
BR112012016783A2
(pt)
|
2010-01-11 |
2015-09-01 |
Orexigen Therapeutics Inc |
"usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
|
EP2531176B1
(de)
|
2010-02-03 |
2016-09-07 |
Grünenthal GmbH |
Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels eines extruders
|
BR112013005194A2
(pt)
|
2010-09-02 |
2016-05-03 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação compreendendo sal inorgânico
|
ES2487244T3
(es)
|
2010-09-02 |
2014-08-20 |
Grünenthal GmbH |
Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
|
US9085570B2
(en)
|
2010-10-11 |
2015-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Substituted benzamides and their uses
|
SI2632927T1
(sl)
|
2010-10-26 |
2016-08-31 |
Mars, Incorporated |
Boronati kot inhibitorji arginaze
|
MX348054B
(es)
|
2011-07-29 |
2017-05-25 |
Gruenenthal Gmbh |
Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
|
MX348491B
(es)
|
2011-07-29 |
2017-06-15 |
Gruenenthal Gmbh |
Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
|
EA026656B1
(ru)
|
2011-11-21 |
2017-05-31 |
Калитера Байосайенсиз Инк. |
Гетероциклические ингибиторы глютаминазы
|
BR112014019988A8
(pt)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
|
MX2014012294A
(es)
|
2012-04-12 |
2015-06-05 |
Ruga Corp |
Benzamidas sustituidas y sus usos.
|
TR201815502T4
(tr)
|
2012-04-18 |
2018-11-21 |
Gruenenthal Gmbh |
Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
LT2858640T
(lt)
|
2012-06-06 |
2020-08-10 |
Nalpropion Pharmaceuticals Llc |
Kompozicija, skirta panaudoti pacientų su aukšta širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
|
MX2015005963A
(es)
|
2012-11-16 |
2015-09-16 |
Calithera Biosciences Inc |
Inhibidores heterociclicos de glutaminasa.
|
ES2938225T3
(es)
|
2013-03-15 |
2023-04-05 |
Univ Leland Stanford Junior |
Compuestos de sondas basadas en la actividad, composiciones y métodos de uso
|
US10154966B2
(en)
|
2013-05-29 |
2018-12-18 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
WO2015078891A1
(en)
|
2013-11-26 |
2015-06-04 |
Farmaceutici Formenti S.P.A. |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
CA2949422A1
(en)
|
2014-05-26 |
2015-12-03 |
Grunenthal Gmbh |
Multiparticles safeguarded against ethanolic dose-dumping
|
WO2015192014A1
(en)
|
2014-06-13 |
2015-12-17 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
BR112017002403A2
(pt)
|
2014-08-07 |
2017-12-05 |
Calithera Biosciences Inc |
formas de cristais de inibidores de glutaminase
|
UY36272A
(es)
|
2014-08-13 |
2016-02-29 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores de los receptores de orexinas
|
EP3212195A4
(de)
|
2014-10-31 |
2018-06-06 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von hiv-assoziierter kognitiver dysfunktion
|
PT3267984T
(pt)
|
2015-03-10 |
2022-03-03 |
Aurigene Discovery Tech Ltd |
Compostos de 1,2,4-oxadiazole e tiadiazole como imunomoduladores
|
JP2018517676A
(ja)
|
2015-04-24 |
2018-07-05 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時放出および溶媒抽出に対する耐性を有する改変防止製剤
|
US10143699B2
(en)
|
2015-06-23 |
2018-12-04 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
KR102305932B1
(ko)
|
2015-06-29 |
2021-09-28 |
플로로놀 인코퍼레이티드 |
갈조류의 고체 약제학적 조성물
|
EP3346991A1
(de)
|
2015-09-10 |
2018-07-18 |
Grünenthal GmbH |
Schutz vor oraler überdosierung mit missbrauchssicheren formulierungen mit sofortiger freisetzung
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
CN108601767A
(zh)
|
2015-10-05 |
2018-09-28 |
卡利泰拉生物科技公司 |
用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
|
CR20210389A
(es)
|
2015-10-30 |
2021-09-16 |
Calithera Biosciences Inc |
Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)
|
EP3377512A4
(de)
|
2015-11-16 |
2019-09-18 |
Ichorion Therapeutics, Inc. |
Nukleinsäure-prodrugs
|
LT3414241T
(lt)
|
2016-02-12 |
2022-08-25 |
Astrazeneca Ab |
Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
|
US10793590B2
(en)
|
2016-06-03 |
2020-10-06 |
President And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
JP7125144B2
(ja)
|
2016-09-09 |
2022-08-24 |
キャリセラ バイオサイエンシーズ, インコーポレイテッド |
エクトヌクレオチダーゼ阻害剤およびその使用方法
|
EP3509583B1
(de)
|
2016-09-09 |
2021-06-30 |
The Regents of the University of California |
Östrogenrezeptorliganden, zusammensetzungen und zugehörige verfahren
|
EP3515449B1
(de)
|
2016-09-26 |
2023-07-12 |
Dana-Farber Cancer Institute, Inc. |
Quinolin-derivate als chromobox (cbx) protein inhibitoren zur behandlung von krebs
|
SI3519050T1
(sl)
|
2016-09-28 |
2023-10-30 |
Medicon Pharmaceuticals, Inc. |
Sestavki za zdravljenje očesnih obolenj
|
JP7030345B2
(ja)
|
2016-09-28 |
2022-03-07 |
メディコン ファーマシューティカルズ,インコーポレイテッド |
眼の状態を処置する組成物および方法
|
JP2020502259A
(ja)
|
2016-11-08 |
2020-01-23 |
カリセラ バイオサイエンシズ,インコーポレイテッド |
アルギナーゼ阻害剤併用療法
|
CN114989205A
(zh)
|
2016-12-22 |
2022-09-02 |
卡里塞拉生物科学股份公司 |
用于抑制精氨酸酶活性的组合物和方法
|
ES2964985T3
(es)
|
2016-12-23 |
2024-04-10 |
Univ Leland Stanford Junior |
Compuestos sonda basados en actividad, composiciones y métodos de uso
|
WO2018136634A1
(en)
|
2017-01-18 |
2018-07-26 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
AU2018223982B2
(en)
|
2017-02-24 |
2022-02-03 |
Merck Patent Gmbh |
1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
|
AU2018242623B2
(en)
|
2017-03-31 |
2024-05-02 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
WO2018223032A1
(en)
|
2017-06-02 |
2018-12-06 |
Stealth Biotherapeutics Corp. |
Crystalline salt forms of sbt-20
|
WO2019018539A1
(en)
|
2017-07-19 |
2019-01-24 |
California Institute Of Technology |
PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
|
CN111194308A
(zh)
|
2017-10-11 |
2020-05-22 |
奥瑞基尼探索技术有限公司 |
3-取代的1,2,4-噁二唑的结晶形式
|
SG11202002386WA
(en)
|
2017-10-31 |
2020-04-29 |
Curis Inc |
Compounds and compositions for treating hematological disorders
|
KR20200083503A
(ko)
|
2017-11-03 |
2020-07-08 |
오리진 디스커버리 테크놀로지스 리미티드 |
Tim-3 경로와 pd-1 경로의 이중 저해제
|
AU2018360389A1
(en)
|
2017-11-06 |
2020-05-07 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|
AR113995A1
(es)
|
2017-12-22 |
2020-07-08 |
Medimmune Ltd |
Moduladores de molécula pequeña del domino de btb de keap1
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
JP2021521280A
(ja)
|
2018-04-12 |
2021-08-26 |
マトルクス セラピューティクス コーポレーション |
弾性線維分解を治療するための組成物及び方法
|
US11155638B2
(en)
|
2018-05-08 |
2021-10-26 |
Rhode Island Hospital |
Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
|
US20210122771A1
(en)
|
2018-06-29 |
2021-04-29 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
CA3107750A1
(en)
|
2018-07-27 |
2020-01-30 |
California Institute Of Technology |
Cdk inhibitors and uses thereof
|
US20220218652A1
(en)
|
2018-09-05 |
2022-07-14 |
The General Hospital Corporation |
Methods of treating cytokine release syndrome
|
EP3870181A4
(de)
|
2018-10-26 |
2022-07-20 |
Keros Therapeutics, Inc. |
Kristallformen eines alk2-inhibitors
|
WO2020150473A2
(en)
|
2019-01-18 |
2020-07-23 |
Dogma Therapeutics, Inc. |
Pcsk9 inhibitors and methods of use thereof
|
BR112021014576A2
(pt)
|
2019-01-25 |
2021-10-05 |
Brown University |
Composições e métodos para tratamento, prevenção ou reversão de inflamação e distúrbios associados à idade
|
EP3917500A2
(de)
|
2019-01-31 |
2021-12-08 |
Elektrofi, Inc. |
Partikelbildung und morphologie
|
US20220175749A1
(en)
|
2019-03-14 |
2022-06-09 |
Astrazeneca Ab |
Lanabecestat for weight loss
|
US20220331300A1
(en)
|
2019-06-03 |
2022-10-20 |
Oita University Institute Of Advanced Medicine, Inc. |
Cyclic amide compounds for rabies treatment and method thereof
|
EP4027978A1
(de)
|
2019-09-13 |
2022-07-20 |
Elektrofi, Inc. |
Zusammensetzungen und verfahren zur abgabe von therapeutischen biologika zur behandlung von krankheiten
|
CN114981243A
(zh)
|
2019-11-12 |
2022-08-30 |
健赞公司 |
用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
AU2020409912A1
(en)
|
2019-12-16 |
2022-06-16 |
Smartin Bio Inc. |
Compounds for inhibiting neovascularization factors and use thereof
|
US20230094393A1
(en)
|
2020-02-07 |
2023-03-30 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
WO2021168271A1
(en)
|
2020-02-19 |
2021-08-26 |
Elektrofi, Inc. |
Droplet formation and particle morphology
|
EP4135667A1
(de)
|
2020-04-17 |
2023-02-22 |
Elektrofi, Inc. |
Verfahren zur herstellung von partikeln durch kontinuierliche tröpfchenbildung und dehydrierung
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
CN111830151B
(zh)
*
|
2020-07-01 |
2021-05-04 |
迪沙药业集团有限公司 |
盐酸安非他酮组合物质量控制用系统适用性对照品
|
EP4192811A1
(de)
|
2020-08-10 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Substituierte 3-amino-4-methylbenzolsulfonamide als kleinmolekülige inhibitoren der ubiquitinspezifischen protease 28
|
AU2021326457A1
(en)
|
2020-08-10 |
2023-03-16 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
CA3191164A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
EP4232161A1
(de)
|
2020-10-23 |
2023-08-30 |
Dana-Farber Cancer Institute, Inc. |
Kovalente inhibitoren der kreatinkinase (ck) und verwendungen davon zur behandlung und prävention von krebs
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
AU2021409394A1
(en)
|
2020-12-21 |
2023-07-27 |
Cornell University |
Peptide-linked drug delivery system
|
WO2022150574A1
(en)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
PE20240327A1
(es)
|
2021-04-13 |
2024-02-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
CA3230259A1
(en)
|
2021-09-03 |
2023-03-09 |
Junkai Liao |
Indole compounds and methods of use
|
WO2023056431A1
(en)
|
2021-10-01 |
2023-04-06 |
Nuvalent, Inc. |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
US20230124705A1
(en)
|
2021-10-01 |
2023-04-20 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
WO2023196900A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024073334A1
(en)
|
2022-09-26 |
2024-04-04 |
Rose Research Center, Llc |
Combination for use in a method of preventing weight gain
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|